Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFONSECA, Leonardo G. Da
dc.contributor.authorHASHIZUME, Pedro H.
dc.contributor.authorOLIVEIRA, Irai Santana de
dc.contributor.authorIZQUIERDO-SANCHEZ, Laura
dc.contributor.authorSAUD, Lisa Rodrigues da Cunha
dc.contributor.authorXERFAN, Mariana Pinheiro
dc.contributor.authorALVES, Venancio Avancini Ferreira
dc.contributor.authorMELLO, Evandro Sobroza de
dc.contributor.authorHERMAN, Paulo
dc.contributor.authorBANALES, Jesus M.
dc.contributor.authorOLIVEIRA, Claudia P.
dc.contributor.authorCARRILHO, Flair J.
dc.date.accessioned2022-08-12T17:15:32Z
dc.date.available2022-08-12T17:15:32Z
dc.date.issued2022
dc.description.abstractSimple Summary A potential relationship between cholangiocarcinoma and metabolic disorders has been suggested, but there is a lack of published data. This study aimed to describe the prevalence of metabolic disorders in a cohort of 122 patients with cholangiocarcinoma and report clinical outcomes. We found a prevalence of 42.6% of metabolic disorders. There was no significant difference in overall survival between patients with or without metabolic disorders, although there was a better survival in the subgroup of patients undergoing surgical resection. This indicates a need to better explore the association between cholangiocarcinoma in a metabolic background. Introduction and objectives: The incidence of cholangiocarcinoma (CCA) has been increasing globally. Although a concomitant increase in the incidence of metabolic disorders might suggest a causal relationship, the data are scarce. We aimed to describe the prevalence of metabolic disorders in patients with CCA and report the clinical features and outcomes. Patients and Methods: Retrospective study including patients with CCA. Patients were divided into: (1) past history of diabetes or/and overweight/obesity (""metabolic disorder group"") and (2) without any of these features (""non-metabolic-disorder group""). A Cox regression model was used to determine the prognostic factors. Results: 122 patients were included. In total, 36 (29.5%) had overweight/obesity, 24 (19.7%) had diabetes, and 8 (6.6%) had both. A total of 29 (23.8%) patients had resectable disease and received upfront surgery. A total of 104 (85.2%) received chemotherapy for advanced/recurrent disease. The overall survival of the cohort was 14.3 months (95% CI: 10.1-17.3). ECOG-PS 0 (p < 0.0001), resectable disease (p = 0.018) and absence of vascular invasion (p = 0.048) were independently associated with better prognosis. The ""metabolic disorder group"" (n = 52) had a median survival of 15.5 months (95% CI 10.9-33.9) vs. 11.5 months (95% CI 8.4-16.5) in the ""non-metabolic-disorder group"" (n = 70) (HR: 1.10; 95% CI 0.62-1.94). Patients with resectable disease in the ""metabolic group"" had longer survival than patients in the ""non-metabolic group"" (43.4 months (95% CI 33.9-NR) vs. 21.8 months (95% CI 8.6-26.9); HR = 0.12, 95% CI 0.03-0.59). Conclusion: Metabolic disorders are frequent among CCA patients. Underlying metabolic comorbidities may be associated with prognosis in resectable CCA. There is a need to explore the mechanism that drives CCA carcinogenesis in a metabolic background.eng
dc.description.indexPubMedeng
dc.identifier.citationCANCERS, v.14, n.14, article ID 3483, 14p, 2022
dc.identifier.doi10.3390/cancers14143483
dc.identifier.eissn2072-6694
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/48581
dc.language.isoeng
dc.publisherMDPIeng
dc.relation.ispartofCancers
dc.rightsopenAccesseng
dc.rights.holderCopyright MDPIeng
dc.subjectliver cancereng
dc.subjectcholangiocarcinomaeng
dc.subjectmetabolic syndromeeng
dc.subjectdiabeteseng
dc.subjectobesityeng
dc.subject.otherintrahepatic cholangiocarcinomaeng
dc.subject.othercancereng
dc.subject.otherpopulationeng
dc.subject.otherdiseaseeng
dc.subject.wosOncologyeng
dc.titleAssociation between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidenceeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryEspanha
hcfmusp.affiliation.countryisoes
hcfmusp.author.externalIZQUIERDO-SANCHEZ, Laura:Univ Basque Country, Biodonostia Hlth Res Inst, Dept Liver & Gastrointestinal Dis, Ikerbasque,UPV EHU,Donostia Univ Hosp,CIBERehd, San Sebastian 48009, Spain
hcfmusp.author.externalBANALES, Jesus M.:Univ Basque Country, Biodonostia Hlth Res Inst, Dept Liver & Gastrointestinal Dis, Ikerbasque,UPV EHU,Donostia Univ Hosp,CIBERehd, San Sebastian 48009, Spain; Univ Navarra, Sch Sci, Dept Biochem & Genet, Pamplona 31080, Spain
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcLEONARDO GOMES DA FONSECA
hcfmusp.contributor.author-fmusphcPEDRO HENRIQUE SHIMITI HASHIZUME
hcfmusp.contributor.author-fmusphcIRAI SANTANA DE OLIVEIRA
hcfmusp.contributor.author-fmusphcLISA RODRIGUES DA CUNHA SAUD
hcfmusp.contributor.author-fmusphcMARIANA PINHEIRO XERFAN
hcfmusp.contributor.author-fmusphcVENANCIO AVANCINI FERREIRA ALVES
hcfmusp.contributor.author-fmusphcEVANDRO SOBROZA DE MELLO
hcfmusp.contributor.author-fmusphcPAULO HERMAN
hcfmusp.contributor.author-fmusphcCLAUDIA PINTO MARQUES SOUZA DE OLIVEIRA
hcfmusp.contributor.author-fmusphcFLAIR JOSE CARRILHO
hcfmusp.description.articlenumber3483
hcfmusp.description.issue14
hcfmusp.description.volume14
hcfmusp.origemWOS
hcfmusp.origem.pubmed35884542
hcfmusp.origem.scopus2-s2.0-85136446672
hcfmusp.origem.wosWOS:000832119200001
hcfmusp.publisher.cityBASELeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAnstee QM, 2013, NAT REV GASTRO HEPAT, V10, P330, DOI 10.1038/nrgastro.2013.41eng
hcfmusp.relation.referenceBanales JM, 2020, NAT REV GASTRO HEPAT, V17, P557, DOI 10.1038/s41575-020-0310-zeng
hcfmusp.relation.referenceBekki Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.776863eng
hcfmusp.relation.referenceBerres ML, 2010, DIGEST DIS, V28, P192, DOI 10.1159/000282085eng
hcfmusp.relation.referenceBoyce CJ, 2010, AM J ROENTGENOL, V194, P623, DOI 10.2214/AJR.09.2590eng
hcfmusp.relation.referenceChaiteerakij R, 2013, HEPATOLOGY, V57, P648, DOI 10.1002/hep.26092eng
hcfmusp.relation.referenceChan KM, 2018, BMC GASTROENTEROL, V18, DOI 10.1186/s12876-018-0912-xeng
hcfmusp.relation.referenceDa Fonseca L.G., 2021, ANN HEPATOL, V24, P100376, DOI [10.1016/j.aohep.2021.100376, DOI 10.1016/J.AOHEP.2021.100376]eng
hcfmusp.relation.referenceDe Lorenzo S, 2020, CANCERS, V12, DOI 10.3390/cancers12113182eng
hcfmusp.relation.referenceDjiogue S, 2013, ENDOCR-RELAT CANCER, V20, pR1, DOI 10.1530/ERC-12-0324eng
hcfmusp.relation.referenceEslam M, 2020, GASTROENTEROLOGY, V158, P1999, DOI 10.1053/j.gastro.2019.11.312eng
hcfmusp.relation.referenceFava G, 2008, CANCER RES, V68, P6752, DOI 10.1158/0008-5472.CAN-07-6682eng
hcfmusp.relation.referenceFoerster F, 2022, J HEPATOL, V76, P446, DOI 10.1016/j.jhep.2021.09.007eng
hcfmusp.relation.referenceGarcia-Jimenez C, 2014, J MOL ENDOCRINOL, V52, pR51, DOI 10.1530/JME-13-0152eng
hcfmusp.relation.referenceGhidini M, 2021, EXPERT REV GASTROENT, V15, P999, DOI 10.1080/17474124.2021.1946393eng
hcfmusp.relation.referenceGraffy PM, 2019, RADIOLOGY, V293, P334, DOI 10.1148/radiol.2019190512eng
hcfmusp.relation.referenceHuang YN, 2017, ONCOTARGET, V8, P100570, DOI 10.18632/oncotarget.20141eng
hcfmusp.relation.referenceIzquierdo-Sanchez L, 2022, J HEPATOL, V76, P1109, DOI 10.1016/j.jhep.2021.12.010eng
hcfmusp.relation.referenceKhan SA, 2019, LIVER INT, V39, P19, DOI 10.1111/liv.14095eng
hcfmusp.relation.referenceKuriyama K, 2020, CANCER SCI, V111, P1969, DOI 10.1111/cas.14421eng
hcfmusp.relation.referenceLamarca A, 2021, LANCET ONCOL, V22, P690, DOI 10.1016/S1470-2045(21)00027-9eng
hcfmusp.relation.referenceMolinari M., 2021, ANN SURG, V2, pe065, DOI [10.1097/AS9.0000000000000065, DOI 10.1097/AS9.0000000000000065]eng
hcfmusp.relation.referenceNagtegaal ID, 2020, HISTOPATHOLOGY, V76, P182, DOI 10.1111/his.13975eng
hcfmusp.relation.referenceNeuschwander-Tetri BA, 2010, HEPATOLOGY, V52, P774, DOI 10.1002/hep.23719eng
hcfmusp.relation.referenceOh DY, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.378eng
hcfmusp.relation.referencePfister D, 2021, NATURE, V592, P450, DOI 10.1038/s41586-021-03362-0eng
hcfmusp.relation.referenceSurapaneni PK, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.288eng
hcfmusp.relation.referenceValle JW, 2016, ANN ONCOL, V27, pv28, DOI 10.1093/annonc/mdw324eng
hcfmusp.relation.referenceValle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721eng
hcfmusp.relation.referenceWelzel TM, 2007, INT J CANCER, V120, P638, DOI 10.1002/ijc.22283eng
hcfmusp.relation.referenceWelzel TM, 2007, CLIN GASTROENTEROL H, V5, P1221, DOI 10.1016/j.cgh.2007.05.020eng
hcfmusp.relation.referenceWijarnpreecha K, 2020, J GASTROINTEST LIVER, V29, P629, DOI 10.15403/jgld-2990eng
hcfmusp.relation.referenceXiong JP, 2018, CANCER MANAG RES, V10, P3849, DOI 10.2147/CMAR.S175628eng
hcfmusp.relation.referenceYang H, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00854eng
hcfmusp.scopus.lastupdate2024-04-18
relation.isAuthorOfPublication928b3d0c-bffc-4a1d-a5f9-c5c077adcc94
relation.isAuthorOfPublication3e4cd671-1468-4b30-a096-ec2c34dfa569
relation.isAuthorOfPublication4984d0a7-ae59-4b24-9413-3e371f5715f0
relation.isAuthorOfPublication7f990e5a-0d48-4c47-8a1e-c873507c643b
relation.isAuthorOfPublicationcfbf4469-0bf5-45fb-b014-81748d559a59
relation.isAuthorOfPublicationdd94c553-33a7-4e49-9541-3c998006d016
relation.isAuthorOfPublication171271b8-0f0b-462e-a8f1-03e1f34fb763
relation.isAuthorOfPublication4a6061ac-5d2f-4385-8340-fdecdd376813
relation.isAuthorOfPublication6fe5bca4-b5ef-47da-b77a-5e60d87e165f
relation.isAuthorOfPublication9221b8d6-ad80-46e5-a56f-fb3b28a8c155
relation.isAuthorOfPublication.latestForDiscovery928b3d0c-bffc-4a1d-a5f9-c5c077adcc94
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_FONSECA_Association_between_Metabolic_Disorders_and_Cholangiocarcinoma_Impact_of_2022.PDF
Tamanho:
618.81 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HC/InRad
Carregar mais